AASK Colhort Study

摘要 高血压肾病通常进展。AASK（Afdcan） 美国肾脏病和高血压研究）队列研究是为了前瞻性地确定 非裔美国人的肾功能病程和肾脏疾病进展的危险因素 患有高血压肾病的患者接受推荐的降压治疗。一 次要目的是确定心血管疾病的发生率并评估其风险 因素 AASK队列研究是一项前瞻性、观察性研究，是AASK试验的扩展。 AASK试验测试了3种药物对肾功能的影响， 抗高血压治疗（雷米普利、美托洛尔和曲马多）和2个血压水平 控制在1 094名试验参与者中，约有650至700人尚未达到 终末期肾病（ESRD）患者可能会入组队列研究。有待研究的风险因素 包括环境、遗传、生理和社会经济变量。主要肾脏 结局是一种复合临床结局，定义为血清肌酐加倍、ESRD或死亡。 高血压的药物治疗，从血管紧张素转换酶抑制剂开始 ，并提供给所有参与者。以这种方式，这项研究直接控制了两个主要的 肾病进展的决定因素（高血压的治疗和肾保护的使用， 抗高血压药物）。队列研究的最短随访时间为5年 （总共9到12年，包括AASK tdal的pedod）。 最终，来自AASK队列研究的数据应该会增强我们对风险因素的理解 以及决定肾脏疾病进展的过程。这样的结果最终可能 导致延迟或预防ESRD的新策略。

ABSTRACT Hypertensive kidney disease commonly progresses. The primary objective of the AASK (Afdcan American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects on kidney function of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the pedod of the AASK tdal). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.